DONNA FELSENSTEIN, M.D.; DONALD J. D'AMICO, M.D.; MARTIN S. HIRSCH, M.D.; DAVID A. NEUMEYER, B.S.; DONNA M. CEDERBERG, M.S.N.; PAULO de MIRANDA, Ph.D.; ROBERT T. SCHOOLEY, M.D.
Cytomegalovirus infections can cause significant morbidity and mortality in immunosuppressed patients, and present antiviral agents have had little efficacy against these infections. We describe the use of an acyclic nucleoside 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine (BW B759U), in the treatment of two patients with cytomegalovirus retinitis. The efficacy of this agent was evident, with healing of retinal lesions and resolution of viremia and viral shedding. BW B759U appears to be similar pharmacokinetically to intravenous acyclovir in terms of half-life, peak serum levels, and renal excretion.
DONNA FELSENSTEIN, DONALD J. D'AMICO, MARTIN S. HIRSCH, DAVID A. NEUMEYER, DONNA M. CEDERBERG, PAULO de MIRANDA, et al. Treatment of Cytomegalovirus Retinitis with 9-[2-Hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Ann Intern Med. 1985;103:377–380. doi: 10.7326/0003-4819-103-3-377
Download citation file:
Published: Ann Intern Med. 1985;103(3):377-380.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use